31/05 – 03/06/2018

ΙΑSIS PHARMA, also contributing to the field of Gynecology, participated successfully in the 14th Panhellenic Conference on Obstetrics and Gynecology, which took place on May 31st- June 3rd, at Megaron Athens International Conference Centre.
The particular meeting is the leading event of the Hellenic Society of Obstetrics and Gyneacology (HSOG). A number of reputable national and international guest speakers participated, introducing the delegates into the latest scientific developments in Obstetrics and Gynecology.
The Healthcare specialists visited IASIS PHARMA exhibition stand, where they were informed about the company’s wide range and high quality medicinal products.

Increased interest was shown for Modiwart®, the new IASIS PHARMA product, with imiquimod as its active ingredient. Modiwart® is an innovative immunomodulator, with the following indications: external genital and anogenital warts (condyloma acuminata) in adults, small superficial basal cell carcinomas (sBCCs) and clinically typical actinic keratosis. Modiwart® is available as a cream (5%) for topical use, in single-use sachets (12 per box).

There was also strong interest for the effervescent line produced in IASIS PHARMA state of the art, manufacturing unit for pharma grade effervescent products.
More specifically:
MAG-IASIS®, a combination of magnesium citrate and magnesium aspartate dihydrate, equivalent to 243 mg of Magnesium
Calciform D3®, in the unique combination of Calcium + Vitamin D(Calcium carbonate+ Cholecalciferol: 1000mg+880 IU) and
Calciform®, Calcium carbonate 500 mg.

Moreover, Combi® was introduced· as a combination of miconazole + fluprednidene in the form of cream with excellent texture and the advantage of the 50g packsize.